StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Management ChangeSep 16, 2026, 08:08 AM

Myriad Genetics Appoints Vishal Sikri EVP, Commercial; CCO Departs

AI Summary

Myriad Genetics, Inc. announced a change in its commercial leadership. Brian Donnelly has departed from his role as Chief Commercial Officer, effective September 16, 2026, and will stay on in a non-executive capacity until September 21 to aid in the transition. Concurrently, Vishal Sikri, previously Senior Vice President of Product, has been appointed as the new Executive Vice President, Commercial, also effective September 16, 2026. The company also reaffirmed its financial guidance for the full-year 2026.

Key Highlights

  • Brian Donnelly no longer serves as Chief Commercial Officer, effective September 16, 2026.
  • Vishal Sikri appointed Executive Vice President, Commercial, effective September 16, 2026.
  • Brian Donnelly to remain as a non-executive employee through September 21, 2026 for transition.
  • Company reaffirms financial guidance for full-year 2026.